Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-27T21:53:38.742Z Has data issue: false hasContentIssue false
  • English
  • Français

149 Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study

Published online by Cambridge University Press:  15 June 2018

Karen E. Anderson ,
Mat D. Davis ,
Stewart A. Factor ,
Robert A. Hauser ,
L. Fredrik Jarskog ,
Joohi Jimenez-Shahed ,
Rajeev Kumar ,
FRCPC ,
Stanislaw Ochudlo  and
William G. Ondo
...Show all authors
Karen E. Anderson
Affiliation:
Georgetown University, Washington, District of Columbia, USA
Mat D. Davis
Affiliation:
Teva Pharmaceutical Industries, Frazer, Pennsylvania, USA
Stewart A. Factor
Affiliation:
Emory University, Atlanta, Georgia, USA
Robert A. Hauser
Affiliation:
University of South Florida Parkinson’s Disease and Movement Disorders Center, Tampa, Florida, USA
L. Fredrik Jarskog
Affiliation:
University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
Joohi Jimenez-Shahed
Affiliation:
Baylor College of Medicine, Houston, Texas, USA
FRCPC
Affiliation:
Rocky Mountain Movement Disorders Center, Englewood, Colorado, USA
Stanislaw Ochudlo
Affiliation:
University Clinical Center of Silesian Medical University, Katowice, Poland
William G. Ondo
Affiliation:
Methodist Neurological Institute, Houston, Texas, USA
Hubert H. Fernandez
Affiliation:
Cleveland Clinic, Cleveland, Ohio, USA
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Tardive dyskinesia (TD) is an involuntary movement disorder resulting from exposure to dopamine-receptor antagonists. In the 12-week ARM-TD and AIM-TD studies, deutetrabenazine demonstrated significant improvements in Abnormal Involuntary Movement Scale (AIMS) scores at Week 12 compared with placebo, and was generally well tolerated.

Objective

To evaluate the efficacy and safety of long-term deutetrabenazine therapy in patients with TD.

Methods

Patients with TD who completed the ARM-TD or AIM-TD studies were eligible to enter this open-label, single-arm, long-term safety study after they completed the 1-week washout period and final evaluation in the blinded portion of the trial. Efficacy endpoints included the change in AIMS score from baseline, and treatment success (defined as “much improved” or “very much improved”) on the Clinical Global Impression of Change (CGIC) and Patient Global Impression of Change (PGIC). This analysis reports results up to Week 54.

Results

304 patients enrolled in the extension study. At Week 54, the mean (standard error) change in AIMS score was –5.1 (0.52). After 6 weeks of deutetrabenazine treatment, the proportion of patients who achieved treatment success was 58% per the CGIC and 53% per the PGIC, and by Week 54 was 72% per the CGIC and 59% per the PGIC, thus demonstrating maintenance or enhancement of benefit over time. Deutetrabenazine was well tolerated for up to 54 weeks, and compared with the ARM-TD and AIM-TD studies, no new safety signals were detected.

Conclusions

54 weeks of deutetrabenazine treatment was generally efficacious, safe, and well tolerated in patients with TD.

Presented at: The American Psychiatric Association 2017 Annual Meeting; May 20–24, 2017; San Diego, California, USA.

Funding Acknowledgements

This study was funded by Teva Pharmaceutical Industries, Petach Tikva, Israel.

Type
Abstracts
Information
CNS Spectrums , Volume 23 , Issue 1 , February 2018 , pp. 92 - 93
Copyright
© Cambridge University Press 2018